Cross-talk between adenosine and the oxatriazole derivative GEA 3175 in platelets

European Journal of Pharmacology

Volumn 517, Issue 3, 2005, Pages 149-157

  Persson, Anna Asplund ^a   Zalavary, Stefan ^b   Lindström, Eva ^a   Whiss, Per A ^a   Bengtsson, Torbjörn ^a   Grenegård, Magnus ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adenosine; Calcium; cAMP; cGMP; GEA 3175; Milrinone; Nitric oxide; Phosphodiesterases; Platelets

Indexed keywords

3 (3 CHLORO 2 METHYLPHENYL) 5 (4 METHYLBENZENESULFONYLIMINO) 1,2,3,4 OXATRIAZOLE; ADENOSINE; ADENOSINE TRIPHOSPHATE; CALCIUM ION; CYCLIC GMP; FIBRINOGEN; MILRINONE; NITRIC OXIDE; OXATRIAZOLE; PADGEM PROTEIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE III INHIBITOR; UNCLASSIFIED DRUG;

ADHESION; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ADENOSINE; BLOOD PLATELETS; CALCIUM; CYCLIC AMP; CYCLIC GMP; CYTOSOL; DRUG INTERACTIONS; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; MILRINONE; OXADIAZOLES; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; QUINOXALINES; THROMBIN; TIME FACTORS; TRIAZOLES;

EID: 22144453537     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.05.019     Document Type: Article

References (33)

1. G. Anfossi, P. Massucco, V. Piretto, E. Mularoni, F. Cavalot, L. Mattiello, and M. Trovati Interplay between milrinone and adenosine in the inhibition of human platelet response Gen. Pharmacol. 27 1996 1149 1154
2. A.K. Asplund Persson, L. Palmer, P. Gunnarsson, and M. Grenegård Characterisation of GEA 3175 on human platelets; comparison with S-nitroso-N-acetylpenicillamine Eur. J. Pharmacol. 496 2004 1 9
3. A. Aszodi, A. Pfeifer, M. Ahmad, M. Glauner, X.-H. Zhou, L. Ny, L.-E. Andersson, B. Kehrel, S. Offermanns, and R. Fässler The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP-and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function EMBO J. 18 1999 37 48
4. K.L. Axelsson, K.E. Bornfeldt, B. Norlander, and J.E.S. Wikberg Attomole sensitive radioimmunoassay for cyclic GMP Second Messengers Phosphoprot. 12 1988 145 154
5. H. Bult, H.R. Fret, F.H. Jordaens, and A.G. Herman Dipyridamole potentiates platelet inhibition by nitric oxide Thromb. Haemost. 66 1991 343 349
6. L. Cavallini, M. Cqassin, A. Borean, and A. Alexandre Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation J. Biol. Chem. 271 1996 5545 5551
7. I.F. Charo, N. Kieffer, and D.R. Phillips Platelet membrane glycoproteins R.W. Colman J. Hirsh V.J. Marder E.W. Salzam In Hemostasis and Thrombosis: Basic Principles and Clinical Practice 3rd ed. 1994 Lippincott Company Philadelphia 489 507
8. 2+-ATPase by cAMP-dependent and tyrosine phosphorylation J. Biol. Chem. 272 1999 15113 15119
9. T.R. Dunkern, and A. Hatzelman The effect of Sidenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5 Cell. Signal. 17 2005 331 339
10. M.A.H. Feijge, K. Ansink, K. Vanschoonbeek, and J.W.M. Heemskerk Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3 Biochem. Pharmacol. 67 2004 1559 1567
11. I.A. Feoktistov, S. Paul, A.S. Hollister, D. Robertson, and I. Biaggioni Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin-and epinephrine-induced platelet stimulation Am. J. Hypertens. 5 1992 147 153
12. B. Furie, B.C. Furie, and R. Flaumenhaft A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion Thromb. Haemost. 86 2001 214 221
13. R. Gerzer, B. Karrenbrock, W. Siess, and J.-M. Heim Direct comparison of the effects of nitroprusside, SIN-1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity Thromb. Res. 52 1988 11 21
14. M. Grenegård, M.C. Gustafsson, R.G.G. Andersson, and T. Bengtsson Synergistic inhibition of thrombin-induced platelet aggregation by the novel nitric oxide-donor GEA 3175 and adenosine Br. J. Pharmacol. 118 1996 2140 2144
15. 2+ indicators with greatly improved fluorescence properties J. Biol. Chem. 260 1985 3440 3450
16. S.A. Harrison, D.H. Reifsnyder, B. Gallis, G.G. Cadd, and J.A. Beavo Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs Mol. Pharmacol. 29 1986 506 514
17. R.J. Haslam, and G.M. Rosson Effects of adenosine on levels of adenosine cyclic 3′,5′-monophosphate in human platelets in relation to adenosine incorporation and platelet aggregation Mol. Pharmacol. 11 1975 528 544
18. R.J. Haslam, N.T. Dickinson, and E.K. Jang Cyclic nucleotides and phosphodiesterases in platelets Thromb. Haemost. 82 1999 412 423
19. I.G.M. Johansson Rydberg, R.G.G. Andersson, and M. Grenegård Effects of the nitric oxide-donor GEA 3175 on guinea pig airways Eur. J. Pharmacol. 329 1997 175 180
20. D. Keh, I. Kurer, K.J. Falke, and H. Gerlach Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine Blood Coagul. Fibrinolysis. 14 2003 327 334
21. J.M. Manns, K.J. Brenna, R.W. Colman, and S.B. Sheth Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases Thromb. Haemost. 87 2002 873 879
22. D.H. Maurice, and R.J. Haslam Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP Mol. Pharmacol. 37 1990 671 681
23. D.H. Maurice, D. Palmer, D.G. Tilley, H.A. Dunkerley, S.J. Netherton, D.R. Raymond, H.S. Elbatarny, and S.L. Jimmo Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system Mol. Pharmacol. 64 2003 533 546
24. S.N. Peterson, and E.G. Lapetina Platelet activation and inhibition. Novel signal transduction mechanisms Ann. N.Y. Acad. Sci. 714 1994 53 63
25. M.W. Radomski, R.M.J. Palmer, and S. Moncada The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide Br. J. Pharmacol. 92 1987 639 646
26. V. Ralevic, and G. Burnstock Receptors for purines and pyrimidines Pharmacol. Rev. 50 1998 415 475
27. B.R. Reep, and E.G. Lapetina Nitric oxide stimulates the phosphorylation of rap1b in human platelets and acts synergistically with iloprost Biochem. Biophys. Res. Commun. 6 1996 1 5
28. E. Salas, M.A. Moro, S. Askew, H.F. Hodson, A.R. Butler, M.W. Radomski, and S. Moncada Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL- penicillamine on human platelets Br. J. Pharmacol. 112 1994 1071 1076
29. W. Siess, B. Grünberg, and K. Luber Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition K.S. Authi S.P. Watson V.V. Kakkar Mechanisms of Platelet Activation and Control 1993 Plenum Press New York 229 235
30. A.L. Steiner, C.W. Parker, and D.M. Kipnis Radioimmunoassay for cyclic nucleotides J. Biol. Chem. 247 1972 1106 1113
31. K. Varani, S. Gessi, A. Dalpiaz, and P.A. Borea Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding Br. J. Pharmacol. 117 1996 1693 1701
32. P.A. Whiss, R.G.G. Andersson, and U. Srinivas Modulation of P-selectin expression on isolated human platelets by an NO-donor assessed by a novel ELISA application J. Immunol. Methods. 200 1997 135 143
33. P.A. Whiss, and R.G.G. Andersson Divalent cations and the protein surface co-ordinate the intensity of human platelet adhesion and P-selectin surface expression Blood Coagul. Fibrinolysis 13 2002 407 416